3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 1/2
1
Status
Active not recruiting
40
Recruiting
19
Completed
12
Terminated
5
Not yet recruiting
2
Suspended
1
No longer available
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Gastrointestinal
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Endocrine
1
CNS
1
Conditions
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Interventions
Specimen Handling
76
Cisplatin
64
Drug Therapy
63
Carboplatin
63
Bevacizumab
63
Magnetic Resonance Spectroscopy
59
Radiotherapy
57
Gemcitabine
54
Cyclophosphamide
54
pembrolizumab
52
Oxaliplatin
49
Capecitabine
49
toripalimab
44
Paclitaxel
40
tislelizumab
39
Standard of Care
39
fludarabine
36
Injections
34
Fluorouracil
34
Biopsy
34
venetoclax
33
Blood Specimen Collection
31
Immune Checkpoint Inhibitors
30
anlotinib
28
Nivolumab
28
Surgical Procedures, Operative
27
Irinotecan
27
Docetaxel
27
Leucovorin
26
Dexamethasone
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Not yet recruiting
×
trametinib
×
1 year
×
Clear all
NCT07468071
2026-04-02
KontRASt-R
Novartis
Phase 1/2
Not yet recruiting
40 enrolled
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled